These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9591787)

  • 1. Bcr/Abl associated leukemogenesis in bcr null mutant mice.
    Voncken JW; Kaartinen V; Groffen J; Heisterkamp N
    Oncogene; 1998 Apr; 16(15):2029-32. PubMed ID: 9591787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
    Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
    Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
    Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
    Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
    Arlinghaus RB
    Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture.
    Witte ON
    Cancer Res; 1993 Feb; 53(3):485-9. PubMed ID: 8425181
    [No Abstract]   [Full Text] [Related]  

  • 8. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute leukaemia in bcr/abl transgenic mice.
    Heisterkamp N; Jenster G; ten Hoeve J; Zovich D; Pattengale PK; Groffen J
    Nature; 1990 Mar; 344(6263):251-3. PubMed ID: 2179728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BCR gene and philadelphia chromosome-positive leukemogenesis.
    Laurent E; Talpaz M; Kantarjian H; Kurzrock R
    Cancer Res; 2001 Mar; 61(6):2343-55. PubMed ID: 11289094
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
    Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
    Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relationship between the persistence of the BCR/ABL gene and relapse in adult patients with acute lymphoblastic leukemia].
    Anguita E; Villegas A; González FA; del Potro E; Martínez R; Alvarez A; Díaz-Mediavilla J; Ferro MT; Espinós D
    Med Clin (Barc); 1999 Apr; 112(13):481-4. PubMed ID: 10353112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
    Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
    Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
    Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
    Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
    Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exon-skipping in BCR/ABL is induced by ABL exon 2.
    Lichty BD; Kamel-Reid S
    Biochem J; 2000 May; 348 Pt 1(Pt 1):63-9. PubMed ID: 10794714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.